← All News
Seeking Alpha · 1 min read

Talphera outlines plan to seek FDA agreement to end NEPHRO enrollment by Dec. 31, 2026, while raising Niyad peak U.S. sales view to over $200M

Talphera outlines plan to seek FDA agreement to end NEPHRO enrollment by Dec. 31, 2026, while raising Niyad peak U.S. sales view to over $200M

This is a summary aggregated from Seeking Alpha. Read the complete article on the original site:

Read full article at Seeking Alpha

Related stories

The hardest part of a fair swap is writing things down while you are still friends

Dev.to · 15 min ago

What Does It Take to Build a Kill Switch for an AI Agent?

Dev.to · 16 min ago

Morgan Rogers scores for England; defends for Cole Palmer

Yahoo Sports · 19 min ago

How to Build Retrieval Architecture: Ranking Signals for Changelog Trackers

Dev.to · 20 min ago

AI Can Draft Your Contracts in Seconds. But Who Reviews Them?

Dev.to · 20 min ago

Barred from competing in Canada, Russia wants world junior hockey tournament relocated or canceled

Yahoo Sports · 20 min ago